At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 104 enrolled
Drug / intervention
PF-07038124 ointment +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 2A, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-07038124 OINTMENT FOR 6 WEEKS IN PARTICIPANTS WITH MILD TO MODERATE ATOPIC DERMATITIS OR PLAQUE PSORIASIS
In Brief
A Phase 2 clinical trial evaluating PF-07038124 ointment and Vehicle ointment for Atopic Dermatitis and Plaque Psoriasis. Completed, enrolled 104 participants across 29 sites in 4 countries.
Detailed Summary
This study is being conducted to provide data on efficacy, safety, tolerability and PK of PF-07038124 ointment versus vehicle control in the treatment of mild to moderate AD and mild to moderate plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis, Plaque Psoriasis
CountriesAustralia, Canada, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartDec 2020
Primary CompletionAug 2021
TodayJul 2026
First PostedDec 11, 2020
Enrollment StartDec 21, 2020
Primary CompletionAug 18, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 5.6 years ago
Interventions
PF-07038124 ointmentdrug
PF-07038124 ointment at 0.01% with QD dosing for 6 weeks
Vehicle ointmentdrug
Vehicle ointment with QD dosing for 6 weeks